Drugs that contain Apalutamide

1. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Mar, 2027

(4 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Sep, 2033

(10 years from now)

US10702508 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Apr, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment in combination with androgen deprivation therapy of non-metastatic, castration-resistant prostate cancer (nmcrpc) that improves metastasis free survival

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in